Trial Profile

A Phase I clinical study evaluating the safety, tolerability, pharmacokinetic characteristics, and preliminary antitumor efficacy of HJ-002-03 tablets in patients with advanced non-small cell lung cancer exhibiting epidermal growth factor receptor (EGFR) mutations

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 27 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

19 Feb 2026 New trial record
13 Feb 2026 According to Jing Medicine Technology media release, completed its first subject enrollment at Shanghai Chest Hospital, the affiliated hospital of Shanghai Jiao Tong University. This initiation marks the commencement of a First-in-Human (FIH) trial in China to treat EGFR TKI resistance in advanced non-small cell lung cancer.
13 Feb 2026 Status changed from planning to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com